Single Doses of the Glucokinase Activator Ly2608204 Reduce Blood Glucose in Healthy Subjects and Patients with Type 2 Diabetes Mellitus (T2dm).

Trial Profile

Single Doses of the Glucokinase Activator Ly2608204 Reduce Blood Glucose in Healthy Subjects and Patients with Type 2 Diabetes Mellitus (T2dm).

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Mar 2013

At a glance

  • Drugs LY 2608204 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 25 Mar 2013 New trial record
    • 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top